Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

This secondary application may serve as an alternative to myeloablative conditioning regimens currently required for ex vivo stem cell treatments. The harsh process uses chemotherapy or ...

In theory, exactly the same CAR-T payloads that are currently being developed and deployed for ex vivo cell therapy could eventually be delivered by these proprietary, engineered viral vectors.

US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy, troculeucel to treat moderate Alzheimer’s disease: Santa Ana, California Saturday, Februar ...

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...